Webinar: Small Molecule vs Antibody Development Challenges
Therapeutics remain the primary focus for life science venture investments. As we all know, pre-clinical development of therapeutics is complicated, time consuming, and capital intensive. In the early stages of development, multiple aspects of a therapeutic product need to be optimized to enhance its drug-like properties. However, given the limited time and resources in the academic setting, what aspects of development should inventors focus on? Before diving into drug development, inventors should ask themselves: What is feasible in an academic setting? What is valued more by the investors? Should it be performed in-house or be out-sourced? How much would it cost?